Review article: A pharmacoeconomic analysis of thrombocytopenia in chronic liver disease

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue SUPPL. 1, 2007, Pages 41-48

  Brown Jr , R S ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKR 501; AMG 531; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ELTROMBOPAG; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERFERON; PEGINTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 11; RIBAVIRIN; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANEMIA; ANTIVIRAL THERAPY; ARTIFICIAL EMBOLISM; BLOOD EXAMINATION; BLOOD TRANSFUSION REACTION; BUDGET; CHRONIC LIVER DISEASE; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; ECONOMIC ASPECT; EDEMA; FLUID RETENTION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART ARRHYTHMIA; HEPATITIS C; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; INFECTION COMPLICATION; IRON OVERLOAD; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STANDARD; SYNCOPE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; LIVER DISEASES; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

EID: 35448976349     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03505.x     Document Type: Review

References (41)

1. Kaushansky K. Thrombopoietin. N Engl J Med 1998 339 : 746 54.
2. Demetri GD. Targeted approaches for the treatment of thrombocytopenia. Oncologist 2001 6 (Suppl. 5 15 23.
3. Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999 6 : 437 41.
4. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006 23 : 1055 65.
5. Wong F. The use of TIPS in chronic liver disease. Ann Hepatol 2006 5 : 5 15.
6. Murphy MF, Waters AH. Clinical aspects of platelet transfusions. Blood Coagul Fibrinolysis 1991 2 : 389 96.
7. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol 2000 37 (Suppl. 4 3 10.
8. Elting LS, Cantor SB, Martin CG, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 2003 97 : 1541 50.
9. Heyman MR, Schiffer CA. Platelet transfusion therapy for the cancer patient. Semin Oncol 1990 17 : 198 209.
10. Snider C, Erder H, LaBrecque I, et al. What are the true costs of platelet transfusions? A prospective time motion study of resource utilization at UCLA medical center. Blood 1996 88 : 333a (Suppl. 1, abstr).
11. Medicare Program - Revisions to Hospital Outpatient Prospective Payment System and Calendar Year 2007 Payment Rates; Final Rule. Fed Reg 77 (November 24, 2006 67960 8401 42 CFR pts 410, 416, et al.).
12. Lill M, Snider C, Calhoun L, et al. Analysis of utilization and cost of platelet transfusions in refractory hematology/oncology patients. Transfusion 1997 37 (Suppl. 26S (abstract).
13. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001 19 : 1519 38.
14. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006 130 : 231 64.
15. Aggarwal A, Ong JP, Younossi ZM, Nelson DR, Hoffman-Hogg L, Arroliga AC. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest 2001 119 : 1489 97.
16. Poordad F, Dalal M, Grotzinger K, Shetty S. Medical resource utilization in chronic liver disease patients with thrombocytopenia [Abstract]. Presented at Digestive Disease Week, May 19-24, 2007, Washington, DC T1647).
17. Cobb WS, Heniford BT, Burns JM, et al. Cirrhosis is not a contraindication to laparoscopic surgery. Surg Endosc 2005 19 : 418 23.
18. Friedman LS. Controversies in liver biopsy: who, where, when, how, why? Curr Gastroenterol Rep 2004 6 : 30 6.
19. Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004 40 : 484 8.
20. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III. Hyattsville, MD : National Center for Health Statistics, 1996.
21. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 2005 42 : 1406 13.
22. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002 36 (Suppl. 1 S30 4.
23. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003 9 : 331 8.
24. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006 24 : 661 72.
25. Bonkovsky HL, Woolley JM. Outcomes research in chronic viral hepatitis C: effects of interferon therapy. Can J Gastroenterol 2000 14 (Suppl. B 21B 9B.
26. Lawrence SP. Advances in the treatment of hepatitis C. Adv Intern Med 2000 45 : 65 105.
27. Afdhal NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin North Am 2004 33 (Suppl. S25 35.
28. Manns MP. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am 2004 33 (Suppl. S11 24.
29. Bacon BR, McHutchison JG. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care 2005 11 (Suppl. S296 306.
30. PEGASYS (peginterferon alfa-2a) Prescribing Information. Nutley, NJ : Hoffman-La Roche Inc. January 2004.
31. McHutchison JG, Manns M, Patel K, et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 9.
32. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004 71 (Suppl. 3 S17 21.
33. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. International Hepatitis Interventional Therapy Group. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003 98 : 2354 62.
34. Malone D, Sullivan S, Black D, et al. The cost of treating chemotherapy-induced thrombocytopenia. J Clin Oncol 1995 14 : 305 (abstr).
35. Calhoun E, Chang C-H, Welshman E, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001 6 : 441 5.
36. Dar Santos AE, Partovi N, Ford JA, Yoshida EM. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. Ann Pharmacother 2007 41 : 268 75.
37. Spiegel BM, Chen K, Chiou CF, Robbins S, Younossi ZM. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol 2005 3 : 1034 42.
38. Tepler I, Elias L, Smith JW II., et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996 87 : 3607 14.
39. Artz AS, Ershler WB, Rustgi V. Interleukin-11 for thrombocytopenia associated with hepatitis C. Clin Gastroenterol 2001 33 : 425 6.
40. Vredenburgh JJ, Hussein A, Fisher D, et al. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Transplant 1998 4 : 134 41.
41. Cantor SB, Elting LS, Hudson DV Jr., Rubenstein EB. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 2003 97 : 3099 106.